Nautilus Biotechnology Inc Cash Flow-to-Debt Ratio
Nautilus Biotechnology Inc cash flow-to-debt ratio. Nautilus Biotechnology Inc (NAUT) has a Cash Flow-to-Debt Ratio of -0.42x as of June 2026, meaning its operating cash flow of $-13.73 Million could theoretically repay 0% of its total liabilities ($32.46 Million) in one year. Check NAUT cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Nautilus Biotechnology Inc (2018–2025)
Cash flow-to-debt ratio of Nautilus Biotechnology Inc from 2018 to 2025. Historical debt coverage capacity for Nautilus Biotechnology Inc across 8 annual periods. Also explore NAUT net assets growth trend to track the company's year-over-year net asset growth rate.
Nautilus Biotechnology Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Nautilus Biotechnology Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Nautilus Biotechnology Inc. For the full cash flow conversion analysis, see NAUT cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.48x | $-50.70 Million | $34.14 Million | ▲ +14.6% |
| 2024 | -1.74x | $-59.15 Million | $34.01 Million | ▼ -35.2% |
| 2023 | -1.29x | $-51.71 Million | $40.21 Million | ▲ +1.4% |
| 2022 | -1.30x | $-45.81 Million | $35.13 Million | ▼ -15.9% |
| 2021 | -1.13x | $-39.24 Million | $34.87 Million | ▼ -822.4% |
| 2020 | -0.12x | $-14.00 Million | $114.73 Million | ▲ +99.4% |
| 2019 | -19.72x | $-9.66 Million | $490.00K | ▼ -1065.2% |
| 2018 | -1.69x | $-238.30 Million | $140.82 Million | — |